Leah Kuntz

Lipocine's oral brexanolone (LPCN 1154) for the treatment of postpartum depression failed to meet the primary endpoint in a phase 3 placebo-controlled trial.

New initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy type 1 and type 2.

Explore fresh clinical insights on schizophrenia—mortality, stigma, cannabis links, lifestyle, and new treatments—and share cases for our April series.

Q1 psychiatric pipeline shifts: wins, setbacks, and standout trials in depression, schizophrenia, Alzheimer disease, and narcolepsy—what to watch next.

Check out the pipeline updates from March!

A panel of experts presented new consensus recommendations focused on the screening, diagnosis, and treatment of tardive dyskinesia among older adults in long-term care settings.

ASAM announces new youth substance use disorder criteria, promoting early intervention, family-focused care, integrated mental health, and updated levels of treatment.

LB Pharmaceuticals has initiated the pivotal phase 3 NOVA-2 trial evaluating the efficacy and safety of LB-102 as a treatment for schizophrenia.

Phase 2 study tests AL001 brain-targeted lithium in bipolar I, aiming to cut toxicity and monitoring via advanced MRI/MRS imaging.

Guy Goodwin, MD, provides insights into COMP360 psilocybin and recent trial results, as well as psychedelics as a whole and their role in psychiatry.

New phase 2 data show HLP004 boosts standard antidepressants for moderate-to-severe GAD.

Phase 2 trial finds BXCL501 eases methadone-taper opioid withdrawal, outperforming lofexidine with simpler dosing and fewer adverse effects.

Explore how stress, sex hormones, and birth control shape mental health—share cases, tips, or CME ideas for our March series.

Check out the pipeline updates from February!

The FDA accepts Teva’s once-monthly olanzapine injection for schizophrenia, promising steadier adherence without mandatory 3-hour monitoring.

Active Minds is pushing for 988 Lifeline information to be shared on student IDs, boosting crisis access and youth-led policy action to curb suicide and reshape campus support.

Phase 3 trial shows COMP360 psilocybin rapidly reduces treatment-resistant depression symptoms with durable effects and good safety, as Compass moves toward FDA review.

Data and Safety Monitoring Board finds no safety issues for buntanetap at 6 months, keeping Annovis’ phase 3 early Alzheimer disease trial on track as enrollment progresses.

A new liquid stimulant option promises up to 14-hour ADHD symptom control and flexible dosing for adults and kids who struggle with capsule medication.

Denovo teams with Orygen to test DB103, a glutamate-targeting therapy, in a phase 2 youth trial for early psychosis.

FDA grants priority review to Takeda’s orexin agonist oveporexton, promising phase 3 gains in wakefulness and cataplexy for narcolepsy type 1.

Congress backs printing 988 on student ID cards, boosting youth crisis access and funding.

Explore insights on bipolar disorder, including suicide risk assessment and comorbidities. Share your insights and experiences today with our February theme!

Check out the pipeline updates from January!

The FDA has accepted for priority review an NDA for Otsuka's centanafadine, a novel ADHD treatment.

LB Pharmaceuticals initiates a phase 2 trial for LB-102, a promising treatment for bipolar depression, aiming to address unmet needs in mood disorders.

What is new in research on major depressive disorder?

Government funding cuts to mental health and addiction programs create chaos, prompting swift restoration amid widespread concern from advocacy groups. Read the statement from the AFSP here.

BioXcel Therapeutics submits an sNDA to the FDA for Igalmi to treat agitation in bipolar disorder and schizophrenia at home.

Seltorexant shows promise as a safe adjunctive treatment for patients with major depressive disorder and insomnia symptoms, with fewer weight changes than quetiapine XR.